1. Search Result
Search Result
Results for "

tumor vascularity

" in MedChemExpress (MCE) Product Catalog:

76

Inhibitors & Agonists

1

Screening Libraries

8

Biochemical Assay Reagents

7

Peptides

1

Inhibitory Antibodies

15

Natural
Products

5

Isotope-Labeled Compounds

8

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0096
    Iloprost
    5 Publications Verification

    Ciloprost; ZK 36374

    Prostaglandin Receptor Endogenous Metabolite Cardiovascular Disease Endocrinology Cancer
    Iloprost (ZK 36374; Ciloprost) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research .
    Iloprost
  • HY-16114
    BNC105
    1 Publications Verification

    Microtubule/Tubulin Cancer
    BNC105 is a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.
    BNC105
  • HY-16147

    Oxi4503; CA1P; Combretastatin A1 diphosphate

    Others Cancer
    Combretastatin A1 phosphate (Oxi4503; CA1P; Combretastatin A1 diphosphate) is a potent vascular disruptive agent. Combretastatin A1 phosphate exerts anti-angiogenic effects on tumors. Combretastatin A1 phosphate has the potential for the research of pancreatic neuroendocrine tumors .
    Combretastatin A1 phosphate
  • HY-W040055

    D-(+)-Neopterin; D-erythro-Neopterin

    NF-κB PPAR ERK Raf Src Cardiovascular Disease Inflammation/Immunology
    Neopterin is an immune system activator metabolized by GTP and can be produced by activated macrophages. Neopterin has the potential to resist vascular inflammation and atherosclerosis. Neopterin inhibits the phosphorylation of NF-κB and promotes the expression of PPAR-γ, thereby suppressing the inflammatory response of vascular endothelial cells, reducing the formation of macrophage foam cells, and regulating the migration and proliferation of vascular smooth muscle cells. Neopterin can be used in research fields such as cardiovascular diseases (such as atherosclerosis), inflammation-related diseases and tumor immunomonitoring .
    Neopterin
  • HY-176347S

    Isotope-Labeled Compounds Cancer
    Alpha Feto Protein, Arg- 13C36, 15N4, Lys- 13C6, 15N2 is the 13C- and 15N-labeled Alpha Feto Protein.
    Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2
  • HY-117836

    FAK Cancer
    FAK-IN-16 (compound OXA-11) is an orally active, selective focal adhesion kinase (FAK) inhibitor with an IC50 of 1.2 pM. FAK-IN-16 inhibits FAK phosphorylation at pFAK[Y397] and pFAK[Y861]. FAK-IN-16 slows tumor growth and reduces tumor vascularity, invasion. FAK-IN-16 potentiates effects of Cisplatin (HY-17394) on tumor cell proliferation and apoptosis in vitro and anti-tumor actions in mice .
    FAK-IN-16
  • HY-A0096R

    Ciloprost (Standard); ZK 36374 (Standard)

    Reference Standards Prostaglandin Receptor Endogenous Metabolite Endocrinology Cancer
    Iloprost (Standard) is the analytical standard of Iloprost. This product is intended for research and analytical applications. Iloprost (ZK 36374; Ciloprost) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research .
    Iloprost (Standard)
  • HY-14919

    MN-029 free base

    Microtubule/Tubulin Cancer
    Denibulin, a novel vascular-disrupting agent, inhibits microtubule assembly reversibly, disrupting tumor vascular endothelial cell cytoskeletons. Denibulin demonstrated tolerability and potential anti-vascular effects, warranting further investigation in cancer therapy .
    Denibulin
  • HY-14815

    Combretastatin A4 phosphate

    Apoptosis Microtubule/Tubulin Cancer
    Fosbretabulin (Combretastatin A4 phosphate) is a vascular disruptor with antitumor activity against atypical thyroid carcinoma (ATC) cell lines and xenografts. Fosbretabulin inhibits tumor growth by inhibiting microtubule polymerization, inducing apoptosis, and suppressing angiogenesis in tumors .
    Fosbretabulin
  • HY-15855

    Microtubule/Tubulin Cancer
    Fosbretabulin (tromethamine), also known as combretastatin A4 phosphate (CA4P), is a vascular disrupting agent evaluated for its efficacy against anaplastic thyroid carcinoma (ATC). It targets tumor neovasculature, causing acute and reversible reductions in tumor blood flow and central necrosis .
    Fosbretabulin tromethamine
  • HY-172272B

    Liposome VEGFR Cancer
    DSPE-PEG5000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
    DSPE-PEG5000-Mal-Cys-ATWLPPR
  • HY-172272A

    Liposome VEGFR Cancer
    DSPE-PEG2000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
    DSPE-PEG2000-Mal-Cys-ATWLPPR
  • HY-172272

    Liposome VEGFR Cancer
    DSPE-PEG1000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
    DSPE-PEG1000-Mal-Cys-ATWLPPR
  • HY-172272C

    Liposome VEGFR Cancer
    DSPE-PEG3400-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
    DSPE-PEG3400-Mal-Cys-ATWLPPR
  • HY-P5107

    LMWP

    VEGFR Cancer
    Low molecular weight protamine is a cell-penetrating peptide with vascular endothelial growth factor (VEGF) inhibitory activity. Low molecular weight protamine can inhibit tumor growth and is used in cancer research .
    Low molecular weight protamine
  • HY-13598

    CKD-516

    Microtubule/Tubulin Cancer
    Valecobulin (CKD516) is a valine proagent of (S516) and a vascular disrupting agent (VDA). Valecobulin is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors .
    Valecobulin
  • HY-169626

    VEGFR Cardiovascular Disease Cancer
    VEGFR-IN-6 (Compound 3) is a vascular endothelial growth factor receptor (VEGFR) inhibitor. VEGFR-IN-6 can inhibit angiogenesis. VEGFR-IN-6 is promising for research of tumor diseases that rely on angiogenesis .
    VEGFR-IN-6
  • HY-103316A
    Ned 19
    3 Publications Verification

    Calcium Channel Cardiovascular Disease Cancer
    Ned 19 is a selective membrane-permeant non competitive NAADP antagonist and inhibits NAADP-mediated Ca 2+ signaling, with an IC50 of 65 nM . Ned 19 strongly inhibits tumor growth and vascularization as well as lung metastases in mice .
    Ned 19
  • HY-10964
    Vadimezan
    Maximum Cited Publications
    58 Publications Verification

    DMXAA; ASA-404

    STING IFNAR Influenza Virus Infection Cancer
    Vadimezan (DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
    Vadimezan
  • HY-177134

    VEGFR c-Met/HGFR Cancer
    Taligantinib (Compound Example 70) is an orally active and selective dual inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) and hepatocyte growth factor receptor (c-Met). Taligantinib suppresses tumor angiogenesis and cell proliferation. Taligantinib is promising for research of solid tumors such as non-small cell lung cancer and hepatocellular carcinoma .
    Taligantinib
  • HY-165603

    Liposome VEGFR FGFR Cardiovascular Disease Inflammation/Immunology Cancer
    Si5-N14 is a key component of siloxane-incorporated lipid nanoparticles (SiLNP), possessing pro-vascular repair and anti-tumor activities. In the transgenic GFP mouse model, Si5-N14 can mediate CRISPR-Cas9 editing. In the Lewis lung carcinoma (LLC) tumor-bearing mouse model, Si5-N14 can knock out the expression of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) to exert an anti-tumor effect. In a mouse model of lung injury induced by viral infection, the delivery of Fibroblast Growth Factor-2 (FGF-2) mRNA via Si5-N14 can promote vascular repair, increase blood oxygen levels, and improve lung function. Si5-N14 shows promise for research in the fields of oncology, pneumonia, and cardiovascular diseases .
    Si5-N14
  • HY-13598A

    CKD-516 hydrochloride

    Microtubule/Tubulin Cancer
    Valecobulin hydrochloride (CKD-516 hydrochloride) is a valine proagent of S516 (HY-130233) and a vascular disrupting agent (VDA). Valecobulin hydrochloride is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors .
    Valecobulin hydrochloride
  • HY-153482

    Small Interfering RNA (siRNA) Cancer
    ATU027 is a siRNA, which silences expression of protein kinase N3 (PKN3) in the vascular endothelium. ATU027 has previously been shown to inhibit local tumor invasion as well as lymph node and pulmonary metastasis in mouse cancer models.
    ATU027
  • HY-153482A

    Small Interfering RNA (siRNA) Cancer
    ATU027 sodium is a siRNA, which silences expression of protein kinase N3 (PKN3) in the vascular endothelium. ATU027 sodium has previously been shown to inhibit local tumor invasion as well as lymph node and pulmonary metastasis in mouse cancer models.
    ATU027 sodium
  • HY-136476B

    Heme Oxygenase (HO) Inflammation/Immunology Cancer
    Cu (II) Protoporphyrin IX is used as a negative control for Zn (II) Protoporphyrin (an inihibitor of heme oxygenase). Heme oxygenase has been implicated in tumor cell resistance to chemotherapy, reduction of free radical formation and inflammation, and associated with vascular repair .
    Cu(II) protoporphyrin IX
  • HY-10338A

    c-Met/HGFR VEGFR Cancer
    Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB .
    Foretinib phosphate
  • HY-172473A

    Liposome Cancer
    DSPE-PEG34000-NGR is a PEG compound which composed of DSPE and an Asn-Gly-Arg (NGR) peptide. NGR peptide can target tumor vascular antigen CD13. DSPE-PEG3400-NGR can be used for drug delivery .
    DSPE-PEG3400-NGR
  • HY-177282

    Somatostatin Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    SST1 receptor antagonist-2 (Example 2) is a piperazine derivative and a somatostatin receptor 1 (SST1) antagonist. SST1 receptor antagonist-2 can be used in the research of psychiatric diseases, neurodegenerative diseases, tumors, as well as vascular disorders and immunological diseases .
    SST1 receptor antagonist-2
  • HY-172474

    Liposome Cancer
    DSPE-PEG5000-NGR is a PEG compound which composed of DSPE and an Asn-Gly-Arg (NGR) peptide. NGR peptide can target tumor vascular antigen CD13. DSPE-PEG5000-NGR can be used for drug delivery .
    DSPE-PEG5000-NGR
  • HY-172472

    Liposome Cancer
    DSPE-PEG1000-NGR is a PEG compound which composed of DSPE and an Asn-Gly-Arg (NGR) peptide. NGR peptide can target tumor vascular antigen CD13. DSPE-PEG1000-NGR can be used for drug delivery .
    DSPE-PEG1000-NGR
  • HY-14444
    Plinabulin
    2 Publications Verification

    NPI-2358

    Microtubule/Tubulin Cancer
    Plinabulin (NPI-2358) is a vascular disrupting agen (VDA) against tubulin-depolymerizing with an IC50 of 9.8 nM against HT-29 cells . Plinabulin binds the colchicine binding site of β-tubulin preventing polymerization and has potent inhibitory to tumor cells .
    Plinabulin
  • HY-172473

    Liposome Cancer
    DSPE-PEG2000-NGR is a PEG compound which composed of DSPE and an Asn-Gly-Arg (NGR) peptide. NGR peptide can target tumor vascular antigen CD13. DSPE-PEG2000-NGR can be used for drug delivery .
    DSPE-PEG2000-NGR
  • HY-119618

    Endogenous Metabolite Cancer
    R1498 is a multi-target kinase inhibitor with anti-angiogenic and anti-proliferative activities. R1498 mainly targets targets such as Aurora kinase and VEGFR2, which are associated with tumor development. R1498 showed moderate in vitro growth inhibition in a variety of tumor cells, with IC50 values in the micromolar range. R1498 showed anti-tumor efficacy superior to sorafenib in a variety of gastric cancer and hepatocellular carcinoma xenograft models, with tumor growth inhibition rates exceeding 80%, and tumor shrinkage was observed in some models. R1498 showed a 10-30% tumor shrinkage rate in three xenograft models derived from human primary gastric cancer tumors, further demonstrating its inhibitory potential. R1498 effectively inhibited Aurora A activity in vivo and reduced tumor vascularization .
    R1498
  • HY-P10869
    dCNP
    1 Publications Verification

    Natriuretic Peptide Receptor (NPR) Inflammation/Immunology Cancer
    dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .
    dCNP
  • HY-16196

    IRC-110160

    Microtubule/Tubulin HIF/HIF Prolyl-Hydroxylase STAT Cancer
    ENMD-1198 (IRC-110160), an orally active microtubule destabilizing agent, is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity. ENMD-1198 is suitable for inhibiting HIF-1alpha and STAT3 in human HCC cells and leads to reduced tumor growth and vascularization.
    ENMD-1198
  • HY-121993

    Wnt Microtubule/Tubulin Cancer
    Combretastatin A-1 is a microtubule polymerization inhibitor that binds to the colchicine-binding site of tubulin. Combretastatin A-1 inhibits the Wnt/β-catenin pathway through tubulin depolymerization mediated AKT deactivation. Combretastatin A-1 exhibits anti-tumor and anti-vascular effects .
    Combretastatin A-1
  • HY-145820

    Apoptosis Microtubule/Tubulin Cancer
    Tubulin inhibitor 14 is a potent NQO2 (quinone oxidoreductase 2) inhibitor with an IC50 of 1.0 μM. Tubulin inhibitor 14 also inhibits tubulin polymerization and the formation of endothelial cell capillary-like tubes. Tubulin inhibitor 14 is a microtubule-destabilizing agent with potential tumor-selectivity and antiangiogenic and vascular disrupting features .
    Tubulin inhibitor 14
  • HY-157148

    c-Met/HGFR Trk Receptor Cancer
    1D228 is a c-Met/TRK inhibitor with antitumor activity. 1D228 inhibits cyclin D1 to induce G0/G1 arrest and inhibit cancer cell proliferation and migration. 1D228 can be used in the study of gastric, liver and vascular tumors .
    1D228
  • HY-N6031
    Dendrophenol
    1 Publications Verification

    Moscatilin

    NF-κB Apoptosis COX HIF/HIF Prolyl-Hydroxylase Wnt β-catenin JNK Cardiovascular Disease Inflammation/Immunology Cancer
    Dendrophenol (Moscatilin) is a NF-κB inhibitor that inhibits inflammation. Dendrophenol exerts potent cytotoxic effect against tumor cells and induces cell cycle arrest and apoptosis. Dendrophenol has antitumor activity. In addition, Dendrophenol can inhibit vascular calcification by inhibiting the activation of WNT3/β-catenin .
    Dendrophenol
  • HY-10964R

    DMXAA (Standard); ASA-404 (Standard)

    STING IFNAR Influenza Virus Infection Cancer
    Vadimezan (Standard) (DMXAA (Standard)) is the analytical standard of Vadimezan (HY-10964). This product is intended for research and analytical applications. Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
    Vadimezan (Standard)
  • HY-P10934

    LXY2

    Integrin Cancer
    LXY3 (LXY2) is a VLA-3-blocking peptide that inhibits the interaction between integrin α3β1 (VLA-3) on neutrophil surfaces and laminin in the basement membrane, thereby preventing neutrophil migration across the tumor vascular basement membrane barrier. LXY3 is used to block neutrophil-mediated nanoparticle release from perivascular pools into the tumor interstitium. LXY3 is commonly employed for targeted imaging of breast cancer .
    LXY3
  • HY-P10770

    Peptide-Drug Conjugates (PDCs) E-Selectin Cardiovascular Disease Cancer
    P-ESBP-DOX is a HPMA copolymer-drug conjugate, which is consistituted of the E-selectin binding peptide and the Doxorubicin (HY-15142). P-ESBP-DOX exhibits cytotoxicity against TNFα-activated human vascular endothelial cells IVECs with an IC50 of 0.28 μM. P-ESBP-DOX can be used in research about tumor vasculature .
    P-ESBP-DOX
  • HY-19471

    Drug Isomer CDK VEGFR Survivin Apoptosis Cancer
    (rac)-ZK-304709 is an isoform of ZK-304709 and is an orally active multi-targeted tumor growth inhibitor that inhibits multiple cell cycle-dependent kinases (CDKs), vascular endothelial growth factor receptor kinases (VEGF-RTKs), and platelet-derived growth factor receptor kinase β (PDGF-RTKβ). (rac)-ZK-304709 can dose-dependently inhibit the proliferation and colony formation of neuroendocrine tumor (NET) cells. (rac)-ZK-304709 directly acts on NET cells by inducing G2 cell cycle arrest and apoptosis, while reducing the expression of MCL1, survivin, and HIF1α. (rac)-ZK-304709 effectively controls tumor growth by inducing apoptosis and inhibiting tumor-induced angiogenesis, and may become a potential agent for inhibiting NET .
    (rac)-ZK-304709
  • HY-169037

    HU-336; Δ8-THCQ

    Apoptosis Cardiovascular Disease Cancer
    Δ8-Tetrahydrocannabinoquinone (HU-336) is a potent antiangiogenic agent. Δ8-Tetrahydrocannabinoquinone inhibits angiogenesis by directly inducing apoptosis of vascular endothelial cells without changing the expression of pro- and antiangiogenic cytokines and receptors. Δ8-Tetrahydrocannabinoquinone is highly effective against tumor xenografts in nude mice .
    Δ8-Tetrahydrocannabinoquinone
  • HY-160853

    Apoptosis Microtubule/Tubulin Cancer
    Tubulin inhibitor 42 (Compound 14b) dose-dependently inhibited the activity of β-microtubulin (IC50 = 3.5 µM).Tubulin inhibitor 42 interferes with microtubule dynamic homeostasis, resulting in the arrest of the cancer cell cycle in the G2/M phase and inducing apoptosis. Tubulin inhibitor 42 significantly inhibits the angiogenic process in vitro and in vivo, preventing vascularization and tumor growth .
    Tubulin inhibitor 42
  • HY-16146

    OXi-4503 tetrasodium

    Wnt Microtubule/Tubulin Cancer
    Combretastatin A-1 phosphate (OXi-4503) tetrasodium, a proagent of Combretastatin A-1, is a microtubule polymerization inhibitor that binds to the colchicine-binding site of tubulin. Combretastatin A-1 phosphate tetrasodium inhibits the Wnt/β-catenin pathway through tubulin depolymerization mediated AKT deactivation. Combretastatin A-1 phosphate tetrasodium exhibits anti-tumor and anti-vascular effects .
    Combretastatin A-1 phosphate tetrasodium
  • HY-P991419

    VEGFR Cancer
    MSB-0254 is a human monoclonal antibody (mAb) targeting VEGFR2/KDR/CD309. MSB-0254 inhibits the invasion, migration, and vascular mimetic (VM) formation of U251 and primary glioma cells. MSB-0254 inhibits the growth of U251 and GL261 cell transplanted tumors. MSB-0254 reduces the expression of CD34, VEGFR2, Ki67, MMP2, MMP9, and CD34/PAS. MSB-0254 can be used in advanced solid tumors research .
    MSB-0254
  • HY-173419

    5-cis-15(R)-Ciloprost; 5-cis-15(R)-ZK 36374

    Drug Isomer Prostaglandin Receptor Endocrinology Cancer
    5-cis-15(R)-Iloprost (5-cis-15(R)-Ciloprost) is the C-5 cis-isomer and 15(R)-epimer of Iloprost (HY-A0096). Iloprost is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research .
    5-cis-15(R)-Iloprost
  • HY-123927

    VEGFR Cardiovascular Disease
    UniPR1331 is a 3β-hydroxy-Δ5-choline acid derivative that inhibits Eph-ephrin interactions. UniPR1331 interacts with VEGFR2 and blocks the interaction of VEGFR2 with its natural ligand vascular endothelial growth factor and subsequent autophosphorylation, signaling, and pro-angiogenic activation of endothelial cells in vitro. UniPR1331 also inhibits tumor cell-driven angiogenesis in zebrafish .
    UniPR1331
  • HY-P10388

    CD47 TGF-β Receptor Cancer
    TAX2 peptide is a dodecapeptide based on molecular docking and simulation design, derived from the cell surface receptor CD47 sequence. TAX2 peptide acts as a selective antagonist of TSP-1 (thromboxin-1) interacting with CD47. TAX2 peptide can promote the binding of TSP-1 to CD36, which leads to the destruction of VEGFR2 (vascular endothelial growth factor receptor 2) activation, thereby blocking downstream NO (nitric oxide) signaling, demonstrating anti-angiogenic properties. TAX2 peptide can be used to study angiogenesis and tumor cell interactions in the tumor microenvironment .
    TAX2 peptide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: